ArticleJournal of nanobiotechnology2026
A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Intravesical therapy is commonly administered after transurethral resection to treat bladder cancer, but it frequently induces chemical cystitis as a side effect. To address this issue, we propose a 'two-in-one' strategy designed to simultaneously enable intravesical chemotherapy and protect normal bladder tissues. A tumor-specific hydrogel serves as a size‑selective filter that excludes entities larger than its pore size, while ensuring sustained and unsaturated drug action. Cell membrane‑derived nanovesicles of tailored sizes were prepared to deliver cytotoxic or protective agents, respectively. Leveraging their homologous targeting ability and competitive diffusion‑enhanced redistribution, these nanovesicles selectively shuttle their cargoes to the intended sites of action. This multifaceted mechanism significantly enhances tumor‑to‑normal tissue selectivity, resulting in 98% tumor inhibition while reducing the incidence of inflammation in normal urothelium by 97%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.